Drug Licenses of 2 Stores of Optival Suspended for 2 days
By Ankur Chandra | Updated at: May 31, 2025 10:43 PM IST
HYDERABAD | May 27, 2025 – MedPlus Health Services Limited (listed as MEDPLUS on NSE and 543427 on BSE) shared that its fully-owned arm, Optival Health Solutions Private Limited, has had the drug licenses of two of its retail pharmacies temporarily suspended — one located in Telangana and the other in Karnataka.
As per the company’s disclosure to the stock exchanges, this action was taken over suspected breaches of Rule 65 under the Drugs and Cosmetics Act of 1940, along with the related rules from 1945.
Regulatory Actions in Detail
| Location | Authority | Order Type | Violation Cited | Date of Order | Estimated Revenue Impact |
|---|---|---|---|---|---|
| Begumpet, Telangana | Assistant Director, Drugs Control Administration, Secunderabad | 2-day Drug License Suspension | Under Rule 65 of Drugs & Cosmetics Act, 1940 | May 25, 2025 | ₹1.14 lakh |
| Haveri, Karnataka | Assistant Director, Drugs Control Administration, Bangalore Circle – Haveri | 2-day Drug License Suspension | Under Rule 65 of Drugs & Cosmetics Act, 1940 | Not stated | ₹0.38 lakh |
Stores Affected
These stores will be shut for two days:
1. Located at Prakash Nagar, Begumpet (Telangana)
2. KSRTC Bus Stop, Haveri (Karnataka)
The shutdown of these stores is expected to result in a revenue loss of approximately ₹1.52 lakh.
Company Statement
The company assured stakeholders that the orders are being addressed in compliance with the applicable laws and regulatory framework. The notice and related details have been made available on the MedPlus corporate website and are also accessible via the BSE and NSE portals.
About MedPlus
Started in 2006 and based in Hyderabad, MedPlus Health Services Ltd has grown to become one of the top pharmacy retail chains in India. With more than 3,000 stores spread across various states, it offers a wide range of medicines, wellness products, diagnostic services, and even online pharmacy options. Over the years, the company has built a strong reputation for smooth operations and staying in line with all regulatory norms.
No material impact on broader operations or financial performance is expected from this isolated event.
REF: https://nsearchives.nseindia.com/corporate/MEDPLUS_26052025194758_Intimation.pdf
